EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined first trimester screening for trisomy 21: Assessment of excess risk in case of free ß‐human chorionic gonadotrophin between 5 and 10 multiples of the median

Anthony Atallah iD, Hélène Leport, Corinne Sault, Benoit De La Fournière, Cyril Huissoud, Marion Cortet

International Journal of Gynecology & Obstetrics · 2023

DOI: 10.1002/ijgo.14722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2023. Verfasst von Anthony Atallah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Maternal-Fetal Medicine and Obstetric Emergency Department, Groupement Hospitalier Est, Hospices Civils de Lyon, Hôpital Femme Mère Enf…. Hauptthemen laut MEDLINE: Down Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The first trimester combined risk of trisomy 21 is obtained by multiplying the risk related to maternal age by the likelihood ratios of nuchal translucency, free beta‐human chorionic gonadotrophin (β‐hCG) and placenta associated plasma protein‐A. Beyond five multiples of the median (MoM) of β‐hCG, the risk of trisomy 21 is truncated. The objective of the present study was to evaluate the evolution of the first trimester combined risk of trisomy 21 in individuals with first‐trimester free‐β‐hCG levels between 5 and 10 MoM.

Methods

We conducted a non‐interventional cohort study from a 6‐year database of combined first‐trimester trisomy 21 screening of all individuals who underwent the screening in a French specialized medical analysis center. We included all pregnant individuals who had a serum‐free β‐hCG between 5 and 10 MoM. Patients for whom the status of the fetus, with or without trisomy 21, was not identified by the outcome of the pregnancy or by a karyotype result were excluded from the study. The discriminatory capacity of free‐β‐hCG above 5 MoM was studied by a receiver operating characteristic curve. We used an orthogonal polynomial regression to represent the evolution of likelihood ratios according to free‐β‐hCG in MoM.

Results

Among 413 216 combined first‐trimester screens of trisomy 21, 2239 (0.5%) screens met the inclusion criteria. In the selected population, 801 (35.8%) were excluded from the study because of missing fetal or neonatal status, and 46 (3.2%) fetuses out of 1438 included were diagnosed with trisomy 21. For free β‐hCG values between 5 and 10 MoM , the area under the curve is 0.56 (0.46–0.65). The scatterplot of the likelihood ratio of β‐hCG showed an increasing parabolic pattern: the likelihood of trisomy 21 increases with the free‐β‐hCG threshold.

Conclusion

To override the truncated risk of trisomy 21 in case of free β‐hCG values between 5 and 10 MoM, the study has allowed us to estimate the adjusted risk of trisomy 21, enabling health professionals to offer appropriate prenatal counseling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromePregnancyFemaleInfant, NewbornHumansPregnancy Trimester, FirstCohort StudiesPrenatal DiagnosisPregnancy-Associated Plasma Protein-AChorionic Gonadotropin, beta Subunit, HumanChorionic GonadotropinBiomarkersTrisomyNuchal Translucency Measurement

Stichwörter der Autor:innen

biomarkershuman chorionic gonadotrophinpregnancyprenatalrisk assessmentscreeningtrisomy 21

Substanzen

Pregnancy-Associated Plasma Protein-AChorionic Gonadotropin, beta Subunit, HumanChorionic GonadotropinBiomarkers

Autor:innen und Institutionen

  • Department of Maternal-Fetal Medicine and Obstetric Emergency Department, Groupement Hospitalier Est, Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Bron, France.
  • Claude Bernard University Lyon 1, Lyon, France.
  • Department of Obstetrics and Gynecology, Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France.
  • Eurofins-Biomnis Laboratory, Lyon, France.
  • Department of Obstetrics and Gynecology, Hospices Civils de Lyon, Croix Rousse University Hospital, Lyon, France.

ORCID-Profile: Anthony Atallah

Zitieren

APA

Atallah, A., Leport, H., Sault, C., De La Fournière, B., Huissoud, C., & Cortet, M. (2023). Combined first trimester screening for trisomy 21: Assessment of excess risk in case of free ß‐human chorionic gonadotrophin between 5 and 10 multiples of the median. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14722

Vancouver

Atallah A, Leport H, Sault C, De La Fournière B, Huissoud C, Cortet M. Combined first trimester screening for trisomy 21: Assessment of excess risk in case of free ß‐human chorionic gonadotrophin between 5 and 10 multiples of the median. International Journal of Gynecology & Obstetrics. 2023. doi:10.1002/ijgo.14722

BibTeX
@article{Atallah2023,
  author = {Atallah, Anthony and Leport, Hélène and Sault, Corinne and De La Fournière, Benoit and Huissoud, Cyril and Cortet, Marion},
  title = {Combined first trimester screening for trisomy 21: Assessment of excess risk in case of free ß‐human chorionic gonadotrophin between 5 and 10 multiples of the median},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2023},
  doi = {10.1002/ijgo.14722}
}
Kostenlos starten →